WO2010071320A2 - 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 - Google Patents
유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 Download PDFInfo
- Publication number
- WO2010071320A2 WO2010071320A2 PCT/KR2009/007382 KR2009007382W WO2010071320A2 WO 2010071320 A2 WO2010071320 A2 WO 2010071320A2 KR 2009007382 W KR2009007382 W KR 2009007382W WO 2010071320 A2 WO2010071320 A2 WO 2010071320A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- udenafil
- release
- composition
- acid
- controlled release
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a controlled release composition for preparing a sustained release formulation containing udenafil.
- Pyrazolopyrimidinone compound represented by the following Chemical Formula 1 (- [2-propyloxy-5- (1-methyl-2-pyrolidinylethtylamidosuphonyl) phenyl] -1-methyl-3-propyl-6,7-dihydro-7H- pyrazolo (4,3-d) pyrimidin-7-one, hereinafter referred to as udenafil, is a type of phosphodiesterase type 5 inhibitor (hereinafter referred to as PDE-5 inhibitor). It is a commercially available product.
- Eudenafil has a strong inhibitory activity against PDE-5, but also has high selectivity, fast absorption, large bioavailability and body distribution volume, and have a half-life of three times that of sildenafil or vadenafil. It is a long drug.
- PDE 5 inhibitors have side effects such as hot flashes, headaches, ocular hyperemia, and nasal congestion.
- Udenafil did not cause any serious adverse reactions by the drug in the phase 1 clinical trials (Korean and Caucasian), most of which were mild.
- the side effects obtained in phase 2 and phase 3 clinical trials showed that the degree and frequency of side effects were lower than those of conventional oral erectile dysfunction drugs.
- Korean Patent Registration Nos. 792126 and 496372 disclose the use of PDE 5 inhibitor-based drugs for the treatment of pulmonary hypertension, portal hypertension, and prostatic hyperplasia.
- Eudenafil is safer than other drugs in the PDE 5 inhibitor family and does not require any special form to treat erectile dysfunction when needed.
- it is possible to control the release of udenafil in drug-dose formulations, thereby reducing initial transient release and continually releasing it for absorption in vivo. It is important to develop a drug that can not only provide sufficient drug effects with a single dose but also minimize possible side effects.
- the class related to the disease is mainly the elderly, patients taking antacids and the like will have a high pH, and patients with gastric ulcer or Solinger Ellison syndrome will have low gastric pH, and the patients will have pulmonary hypertension, portal hypertension, and prostate.
- the sustained-release preparation containing eudenafil is required to be able to freely control the release time of the drug between 3 and 24 hours by releasing the drug constantly regardless of pH in the stomach and intestine.
- Korean Patent Application Publication No. 2004-83492 discloses an osmotic delivery system
- Korean Patent Application Publication No. 2002-70330 discloses a hydrogel-based drug administration behavior
- International Publication No. 2007/057762 discloses an osmotic delivery system.
- the release formulation is disclosed, the controlled release formulation is subjected to several tablet compression processes, insoluble permeable coating, and the final manufacturing process, such as laser perforation has a very complicated and difficult disadvantages.
- Korean Patent Publication Nos. 2001-36527 and 2007-100023 disclose only fast-acting formulations in which sildenafil is released in about a few minutes.
- the inventors of the present invention while studying to prepare a sustained-release preparation containing udenafil, not only does the udenafil-containing composition according to the present invention exhibit the effect of controlled release, but is free of the drug without being affected by any pH in vivo.
- Sustained release of udenafil which is confirmed to be controlled for release and can reduce the possibility of side effects even if administered for a long time for the purpose of treating pulmonary hypertension, portal hypertension, prostatic hyperplasia, and erectile dysfunction from the udenafil containing controlled release composition
- a eudenafil-containing controlled release composition is readily available that can be easily prepared from the formulation.
- the present invention can be used for the treatment of pulmonary arterial hypertension, portal hypertension, prostatic hyperplasia, and prevention of erectile dysfunction. It is an object to provide a controlled release composition for preparing a sustained release formulation containing a pill.
- the present invention relates to a controlled release composition for preparing a sustained release formulation containing udenafil.
- Eudenafil can be usefully used for the treatment of pulmonary arterial hypertension, portal hypertension, prostatic hyperplasia and erectile dysfunction.
- the preparation for the treatment of the indications may cause side effects due to long-term use, it is necessary to control the prolonged or extended in vivo release in order to develop the udenafil as a preparation for applying the indication
- the class related to the disease is mainly the elderly, patients taking antacids and the like will have a high pH, and patients such as gastric ulcer or Solinger Ellison syndrome will have a low gastric pH.
- Edenafil-containing sustained-release preparations should be capable of releasing drugs in a constant irrespective of pH in the stomach and intestinal tract, and should be capable of producing a controlled release formulation for controlled release even using conventional manufacturing methods.
- the controlled release composition for preparing a sustained release formulation containing udenafil in the present invention is
- composition should be able to release the drug constantly regardless of pH in the stomach and intestines.
- the controlled release composition for preparing a sustained-release preparation containing udenafil includes (A) udenafil and a pharmaceutically acceptable salt, (B) solubility modifier, Provided is a eudenafil-containing controlled release composition comprising (C) an adsorbent and (D) a hydrophilic polymer.
- the present invention is characterized in that, in preparing the controlled release composition for preparing a sustained release formulation containing udenafil, the solubility modifier is contained in the controlled release composition containing udenafil.
- the solubility regulator according to the present invention is preferably an organic acid such as citric acid, malic acid, adipic acid, maleic acid, ascorbic acid, succinic acid, tartaric acid, and most preferably citric acid.
- PDE-5 inhibitors are mostly weakly basic drugs that have high solubility in acidity and lower in solubility toward basicity.
- Udenafil a weakly basic drug, also has an excellent solubility in which most of the dosage is dissolved in acid, so that the preparation can be made without any limitation in the preparation of immediate release formulations, but PDE-5 inhibitors are prepared as controlled release release formulations. In this case, the dissolution rate in the release control film is changed due to the difference in solubility according to pH.
- the present invention provides a high concentration of udenafil by solubilizing the hydrated gel matrix by containing a solubility modifier in the hydrated gel matrix so that the drug can be continuously released in the stomach as well as in the intestine without being affected by pH. .
- organic acids as solubilizers for weakly basic drugs such as eudenafil, which is the active ingredient of the present invention, is already known in International Publication No. 2001/47500 and International Publication No. 97/18814.
- the granules are prepared by mixing organic acids with weakly-based udenafil according to the known technique, the granules are very sticky, which causes granulation and tableting.
- the present invention is characterized in that the controlled release composition for preparing a sustained release formulation containing udenafil to solve the above problems is to include an adsorbent without using a binder.
- the amount of excipient used must be greatly increased, in which case the dosage form may be too large to make the patient difficult to take.
- silicon dioxide, calcium silicate, talc and aluminum magnesium metasilicate are used as adsorbents in order to maintain a small tablet size and improve the stickiness of granules, and the stickiness of the granule itself serves as a binder. Even without drying, it is possible to maintain excellent granule properties even after drying.
- the present invention is characterized by the use of high viscosity hydrophilic polymers in controlled release compositions for the preparation of sustained release formulations containing udenafil to control the release of udenafil.
- the high viscosity hydrophilic polymer according to the present invention includes hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxide, xanthan gum, guar gum, locust bean gum, sodium alginate, and the like. Oxides are particularly preferred.
- the high-viscosity hydrophilic polymer acts as a barrier for the active ingredient udenafil to form a gel when it comes in contact with water, thereby leaving the active ingredient out of the formulation, and using the polymer type, weight ratio, and viscosity
- the composition can be freely adjusted to the elution time between 3 to 24 hours.
- the controlled release composition for preparing the sustained release formulation containing the eudenafil according to the present invention may be constantly dissolved regardless of pH in the stomach and intestinal tract so that the absorption in the entire stomach and intestinal tract is constant. Therefore, the composition according to the present invention is constantly dissolved regardless of pH in the gastrointestinal and intestinal tract, even if the patient has a pH dependency, such as a patient taking an elderly person or an antacid, or a patient such as gastric ulcer or Solinger Ellison syndrome. Absorption can be made constant in the human body, thereby reducing the variation between individuals and preventing initial bursts in drug release, thereby reducing drug-related side effects by reducing the maximum blood concentration (Cmax).
- Cmax maximum blood concentration
- the composition of the present invention may further include a pore forming agent.
- the pore-forming agent used in the present invention includes sugars such as lactose, sucrose, mannitol and erythritol, water-soluble salts such as sodium chloride and potassium chloride, or polymers such as polyethylene glycol, and preferably polyethylene glycol may be used.
- the pore forming agent can further control the release of the drug by providing a movable pore of water when the high viscosity hydrophilic polymer to form a gel.
- composition of the present invention may further include an expanding agent.
- the swelling agent used in the present invention includes croscarmellose sodium, sodium starch glycolate, and the like, and preferably sodium starch glycolate may be used.
- the swelling agent can absorb water at a high rate in contact with moisture, gel the water-soluble polymer rapidly inside, and at the same time swell the tablet to help sustained and consistent drug release from the formulation.
- the controlled release composition of the present invention may further include a diluent or a lubricant.
- a diluent or a lubricant examples include lactose, mannitol, microcrystalline cellulose, and the like, and mixtures thereof.
- the diluent allows to form a formulation of a certain size and provides sufficient binding force when tableting.
- the lubricant may include magnesium stearate, calcium stearate, stearic acid, talc, aerosil, castor oil, sodium stearyl fumarate, etc., which provide sufficient fluidity during tableting and prevent binding between punch and die. do.
- the present invention also provides a method for producing a controlled release composition for preparing a sustained release formulation containing eudenafil.
- Method for producing a controlled release composition for preparing a sustained release formulation containing udenafil comprises the steps of preparing a granule by adsorbing a solution mixed with a udenafil or a salt thereof and a solubility modifier on the adsorbent surface;
- a pore-forming agent, an expanding agent, a diluent or a lubricant may be additionally mixed.
- the controlled release composition for preparing the sustained release formulation containing the udenafil according to the present invention can not only be constant absorption in the entire gastrointestinal and intestinal tract by the constant drug release regardless of pH, but also the release time of the drug Can be freely controlled between 3 and 24 hours, and in particular, it can reduce the variation between individuals and prevent the initial burst in drug release, thereby reducing the drug-related side effects by reducing the maximum blood concentration (Cmax) more than necessary You can.
- Cmax maximum blood concentration
- controlled release composition for preparing the sustained-release preparation containing udenafil according to the present invention can improve the stickiness of the granules caused by the main component and the organic acid during the manufacturing process can reduce the dosage form of the tablet, Easy to manufacture
- Figure 1 shows the dissolution test results of the controlled release formulation prepared by the method of Examples 1 to 4,
- Figure 2 shows the comparison of the dissolution test results of the formulation prepared by the method of Example 4 and Comparative Examples 3 to 6,
- Figure 3 shows the results of the dissolution test of the controlled release formulation of Example 4 at various pH.
- Adsorption granules were prepared for the preparation of the udenafil controlled release composition with the composition of Examples 1 to 4 described in Table 1 below.
- hydroxypropyl cellulose which is a water-soluble polymer
- cellulose 80 which is a diluent
- the controlled release composition for preparing the sustained-release preparation prepared in 2) was molded into a 10KP tablet tablet press so that the amount of the main ingredient per tablet was 75mg, thereby preparing a sustained-release tablet.
- the udenafil controlled-release preparation was prepared in the same manner as in Examples 1 to 4, 2) and 3), using the composition shown in Table 3 below. It manufactured and it was set as Example 5-12.
- HPC-LF hydroxypropylmethylcellulose 4000SR, an aqueous release control substance, was added to 7.5, 10, 15, and 20% of each tablet, and then mixed with Celactose 80, followed by 1.9 parts by weight of sodium stearyl fumarate.
- the mixture was mixed again and molded into 10 KP using a tablet press so that the amount of the main component per tablet was 75 mg, thus preparing tablets, which were set as Comparative Examples 3 to 6, respectively.
- the sustained-release controlled release formulation of Example 4 was eluted with a paddle method (50 rpm) in pH 1.2, 4.0, 6.8 and distilled water according to the method of the Korean Pharmacopoeia, and the results are shown in FIG. 3. As shown in Figure 3, the controlled release formulation of Example 4 was confirmed to release the udenafil at a constant rate regardless of the pH in a wide pH range.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
- 유데나필 및 약학적으로 허용가능한 염;구연산, 말산, 아디프산, 말레인산, 아스코르빈산, 숙신산 또는 주석산의 유기산 중에서 선택되는 용해도 조절제;이산화규소, 규산칼슘, 탈크 및 알류미늄 마그네슘 메타실리케이트 중에서 선택되는 흡착제; 및히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 히드록시프로필메틸셀룰로오스, 폴리에틸렌옥사이드, 잔탄검, 구아검, 로커스트빈검 또는 알긴산나트륨 중에서 선택되는 친수성 폴리머를 포함하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 용해도 조절제는 구연산인 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 흡착제는 이산화규소인 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 친수성 폴리머는 히드록시프로필메틸셀룰로오스 또는 폴리에틸렌옥사이드 중에서 선택되는 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 공극형성제를 추가적으로 포함하는 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 팽창화제를 추가적으로 포함하는 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 희석제를 추가적으로 포함하는 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 제 1 항에 있어서, 활택제를 추가적으로 포함하는 것을 특징으로 하는 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물.
- 유데나필 및 약학적으로 허용가능한 염과 구연산, 말산, 아디프산, 말레인산, 아스코르빈산, 숙신산 또는 주석산의 유기산 중에서 선택되는 용해도 조절제가 혼합된 용액을 이산화규소, 규산칼슘, 탈크 및 알류미늄 마그네슘 메타실리케이트 중에서 선택되는 흡착제 표면에 흡착시켜 과립을 제조하는 단계; 및상기 제조된 흡착 과립을 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 히드록시프로필메틸셀룰로오스, 폴리에틸렌옥사이드, 잔탄검, 구아검, 로커스트빈검 또는 알긴산나트륨 중에서 선택되는 친수성 폴리머와 혼합하여 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물의 제조 방법.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0923003A BRPI0923003A2 (pt) | 2008-12-17 | 2009-12-10 | composição de liberação controlada para produção de uma preparação de liberação prolongada contendo udenafil |
CN2009801562658A CN102307597A (zh) | 2008-12-17 | 2009-12-10 | 用于制备含乌地那非缓释制剂的控释组合物 |
RU2011129643/15A RU2480240C2 (ru) | 2008-12-17 | 2009-12-10 | Композиция с контролируемым высвобождением для производства препарата замедленного высвобождения, содержащего уденафил |
US13/140,241 US20110250279A1 (en) | 2008-12-17 | 2009-12-10 | Controlled-release composition for producing sustained-release preparation containing udenafil |
MX2011006450A MX2011006450A (es) | 2008-12-17 | 2009-12-10 | Composicion de liberacion controlada para producir una preparacion de liberacion sostenida que contiene udenafil. |
EP09833598A EP2374479A4 (en) | 2008-12-17 | 2009-12-10 | CONTROLLED RELEASE COMPOSITION FOR PRODUCING LONG-TERM RELEASE PREPARATION CONTAINING UDEAFIL |
AU2009327758A AU2009327758A1 (en) | 2008-12-17 | 2009-12-10 | Controlled-release composition for producing sustained-release preparation containing udenafil |
CA2746190A CA2746190A1 (en) | 2008-12-17 | 2009-12-10 | Controlled-release composition for producing sustained-release preparation containing udenafil |
MA33942A MA33022B1 (fr) | 2008-12-17 | 2009-12-10 | Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil |
SG2011042561A SG172084A1 (en) | 2008-12-17 | 2009-12-10 | Controlled-release composition for producing sustained-release preparation containing udenafil |
JP2011542002A JP2012512242A (ja) | 2008-12-17 | 2009-12-10 | ウデナフィル含有徐放性製剤を製造するための制御放出組成物 |
ZA2011/04445A ZA201104445B (en) | 2008-12-17 | 2011-06-15 | Controlled-release composition for producing sustained-release preparation containing udenafil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0128499 | 2008-12-17 | ||
KR1020080128499A KR101004205B1 (ko) | 2008-12-17 | 2008-12-17 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010071320A2 true WO2010071320A2 (ko) | 2010-06-24 |
WO2010071320A3 WO2010071320A3 (ko) | 2010-09-30 |
Family
ID=42269213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007382 WO2010071320A2 (ko) | 2008-12-17 | 2009-12-10 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110250279A1 (ko) |
EP (1) | EP2374479A4 (ko) |
JP (1) | JP2012512242A (ko) |
KR (1) | KR101004205B1 (ko) |
CN (1) | CN102307597A (ko) |
AU (1) | AU2009327758A1 (ko) |
BR (1) | BRPI0923003A2 (ko) |
CA (1) | CA2746190A1 (ko) |
MA (1) | MA33022B1 (ko) |
MX (1) | MX2011006450A (ko) |
RU (1) | RU2480240C2 (ko) |
SG (1) | SG172084A1 (ko) |
WO (1) | WO2010071320A2 (ko) |
ZA (1) | ZA201104445B (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102871997B (zh) * | 2011-07-12 | 2013-11-13 | 山东绿叶制药有限公司 | 含有去甲基文拉法辛苯甲酸酯类化合物的缓释药物组合物 |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
JP2017524705A (ja) * | 2014-08-12 | 2017-08-31 | メジオン ファーマ カンパニー リミテッド | ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法 |
WO2016168077A1 (en) * | 2015-04-16 | 2016-10-20 | Bpsi Holdings, Llc | Stabilized polyethylene oxide compositions |
KR102249155B1 (ko) * | 2019-07-26 | 2021-05-07 | 주식회사 코아팜바이오 | 유데나필을 함유하는 약제학적 조성물 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018814A1 (en) | 1995-11-21 | 1997-05-29 | Pfizer Research And Development Company, N.V./S.A. | Pharmaceutical formulations |
KR0136527Y1 (ko) | 1993-11-30 | 1999-03-20 | 이대원 | 와이어 본딩 헤드 |
WO2001047500A1 (en) | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Hydrogel-driven drug dosage form |
KR200270330Y1 (ko) | 2001-10-09 | 2002-04-03 | 이대범 | 퍼머용 아이롱 |
KR100496372B1 (ko) | 1999-11-02 | 2005-06-21 | 화이자 인코포레이티드 | 폐고혈압증의 치료 |
KR20070057762A (ko) | 2004-06-07 | 2007-06-07 | 프레제니우스 메디칼 케어 도이칠란드 게엠베하 | 캡, 복막 투석용 검출 장치, 복막 투석용 백 세트 및 이의 이용 방법 |
KR20070100023A (ko) | 2006-04-06 | 2007-10-10 | 한미약품 주식회사 | Pde-5 억제제의 경구용 속용제형 |
KR100792126B1 (ko) | 2006-04-04 | 2008-01-04 | 동아제약주식회사 | 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제 |
KR200483492Y1 (ko) | 2015-03-31 | 2017-05-22 | 산제트 인터내셔널 컴퍼니, 리미티드 | 공작기계의 지능형 제어 시스템 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
EP2127642A3 (en) * | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
EP2153825A1 (en) | 1998-08-27 | 2010-02-17 | Pfizer Health AB | Therapeutic formulation for administering tolterodine with controlled release |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
WO2000054777A1 (en) * | 1999-03-16 | 2000-09-21 | Pentech Pharmaceuticals, Inc. | Controlled release of sildenafil delivered by sublingual or buccal administration |
EA006777B1 (ru) | 2001-06-22 | 2006-04-28 | Пфайзер Продактс Инк. | Фармацевтические композиции адсорбатов аморфного лекарственного средства |
PT1404300E (pt) * | 2001-06-22 | 2009-11-09 | Bend Res Inc | Composições farmacêuticas de dispersões de fármacos e polímeros neutros |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
BRPI0609598A2 (pt) | 2005-03-29 | 2010-04-20 | Roehm Gmbh | forma farmacêutica multiparticulada compreendendo péletes com uma substáncia possuindo um efeito modular em relação à liberação de ingrediente ativo |
EP1898879A1 (en) * | 2005-06-23 | 2008-03-19 | Schering Corporation | Rapidly absorbing oral formulations of pde5 inhibitors |
KR100912680B1 (ko) * | 2006-03-16 | 2009-08-19 | (주) 벡스코아 | 제어 방출 제형 |
KR100780479B1 (ko) * | 2006-05-08 | 2007-11-28 | 윈셋파마 주식회사 | 이부딜라스트 함유 경구용 제제 및 이의 제조방법 |
KR100791844B1 (ko) * | 2006-06-30 | 2008-01-07 | 주식회사유한양행 | 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법 |
US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
-
2008
- 2008-12-17 KR KR1020080128499A patent/KR101004205B1/ko active IP Right Grant
-
2009
- 2009-12-10 WO PCT/KR2009/007382 patent/WO2010071320A2/ko active Application Filing
- 2009-12-10 EP EP09833598A patent/EP2374479A4/en not_active Withdrawn
- 2009-12-10 AU AU2009327758A patent/AU2009327758A1/en not_active Abandoned
- 2009-12-10 US US13/140,241 patent/US20110250279A1/en not_active Abandoned
- 2009-12-10 SG SG2011042561A patent/SG172084A1/en unknown
- 2009-12-10 CA CA2746190A patent/CA2746190A1/en not_active Abandoned
- 2009-12-10 BR BRPI0923003A patent/BRPI0923003A2/pt not_active IP Right Cessation
- 2009-12-10 JP JP2011542002A patent/JP2012512242A/ja not_active Abandoned
- 2009-12-10 MX MX2011006450A patent/MX2011006450A/es not_active Application Discontinuation
- 2009-12-10 CN CN2009801562658A patent/CN102307597A/zh active Pending
- 2009-12-10 MA MA33942A patent/MA33022B1/fr unknown
- 2009-12-10 RU RU2011129643/15A patent/RU2480240C2/ru not_active IP Right Cessation
-
2011
- 2011-06-15 ZA ZA2011/04445A patent/ZA201104445B/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0136527Y1 (ko) | 1993-11-30 | 1999-03-20 | 이대원 | 와이어 본딩 헤드 |
WO1997018814A1 (en) | 1995-11-21 | 1997-05-29 | Pfizer Research And Development Company, N.V./S.A. | Pharmaceutical formulations |
KR100496372B1 (ko) | 1999-11-02 | 2005-06-21 | 화이자 인코포레이티드 | 폐고혈압증의 치료 |
WO2001047500A1 (en) | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Hydrogel-driven drug dosage form |
KR200270330Y1 (ko) | 2001-10-09 | 2002-04-03 | 이대범 | 퍼머용 아이롱 |
KR20070057762A (ko) | 2004-06-07 | 2007-06-07 | 프레제니우스 메디칼 케어 도이칠란드 게엠베하 | 캡, 복막 투석용 검출 장치, 복막 투석용 백 세트 및 이의 이용 방법 |
KR100792126B1 (ko) | 2006-04-04 | 2008-01-04 | 동아제약주식회사 | 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제 |
KR20070100023A (ko) | 2006-04-06 | 2007-10-10 | 한미약품 주식회사 | Pde-5 억제제의 경구용 속용제형 |
KR200483492Y1 (ko) | 2015-03-31 | 2017-05-22 | 산제트 인터내셔널 컴퍼니, 리미티드 | 공작기계의 지능형 제어 시스템 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2374479A4 |
Also Published As
Publication number | Publication date |
---|---|
CN102307597A (zh) | 2012-01-04 |
EP2374479A4 (en) | 2012-09-12 |
BRPI0923003A2 (pt) | 2015-12-15 |
AU2009327758A1 (en) | 2011-07-07 |
WO2010071320A3 (ko) | 2010-09-30 |
KR20100069939A (ko) | 2010-06-25 |
KR101004205B1 (ko) | 2010-12-24 |
MA33022B1 (fr) | 2012-02-01 |
SG172084A1 (en) | 2011-07-28 |
MX2011006450A (es) | 2011-07-28 |
EP2374479A2 (en) | 2011-10-12 |
JP2012512242A (ja) | 2012-05-31 |
RU2011129643A (ru) | 2013-01-27 |
ZA201104445B (en) | 2012-03-28 |
CA2746190A1 (en) | 2010-06-24 |
US20110250279A1 (en) | 2011-10-13 |
RU2480240C2 (ru) | 2013-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101367814B1 (ko) | 위장체류 제제 및 이의 제조 방법 | |
WO2014142616A1 (ko) | 1일 1회 투여로 약리학적 임상 효과를 제공하는 모사프리드 서방성 제제 | |
WO2010071320A2 (ko) | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 | |
KR20030023879A (ko) | 알렌드로네이트 및/또는 기타 비스-포스포네이트의 지연형위 방출을 위한 조성물 및 제형 | |
WO2013147462A1 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
WO2011053003A2 (en) | Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer | |
WO2015093796A1 (en) | Film coated tablet containing choline alfoscerate and process for preparing the same | |
WO2013058450A1 (ko) | 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제 | |
WO2020138791A2 (ko) | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 | |
WO2016060365A1 (ko) | 메트포르민 서방성 제제 및 그의 제조방법 | |
US20070104789A1 (en) | Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone | |
WO2022050670A1 (en) | Pharmaceutical compositions in a tablet form comprising omeprazole, esomeprazole, or a pharmaceutically acceptable salt thereof and processes for preparing the same | |
EP3648745A1 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
CA2683611A1 (en) | Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof | |
WO2019107859A1 (ko) | 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법 | |
WO2013032206A1 (ko) | 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법 | |
WO2022050669A1 (en) | Controlled release pharmaceutical compositions in a monolithic matrix tablet form comprising rebamipide and processes for preparing the same | |
KR101387839B1 (ko) | Ph-의존성 용해도를 갖는 활성 성분의 연장 방출형 제제 | |
CN115209875A (zh) | 用于口服施用的药物组合物 | |
WO2020017808A1 (ko) | 날푸라핀 함유 구강붕해정 | |
WO2021075926A1 (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 약학적 조성물 | |
WO2020036284A1 (ko) | 실로스타졸 서방성 제제 | |
WO2024147572A1 (ko) | 베타네콜을 함유하는 안정한 방출 제어형 약제학적 조성물 및 이의 제조방법 | |
WO2024155042A1 (ko) | 모사프리드 서방성 제제 | |
WO2021125788A1 (ko) | 수니티닙 염산염을 포함하는 경구용 고형제제 및 그 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980156265.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09833598 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2746190 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009833598 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011501189 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4143/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011542002 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009327758 Country of ref document: AU Ref document number: 593488 Country of ref document: NZ Ref document number: MX/A/2011/006450 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13140241 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009327758 Country of ref document: AU Date of ref document: 20091210 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2011000490 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011129643 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0923003 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110617 |